Navigation Links
New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS

WASHINGTON, Nov. 24 /PRNewswire-USNewswire/ -- America's pharmaceutical research and biotechnology companies are testing 97 medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). December 1 marks the 21st anniversary of "World AIDS Day" - a global awareness campaign that originated at the 1988 World Summit of Ministers of Health on Programmes for AIDS Prevention.

"We are greatly encouraged by these critically important medicines and vaccines in development to treat and prevent HIV infection," says PhRMA President and CEO Billy Tauzin. "Pharmaceutical researchers are continuing their efforts to develop new therapies and vaccines to improve and lengthen the lives of HIV-infected patients."

The report found that the 97 products in development include 23 vaccines and 54 antivirals. These drugs are either in human clinical trials or awaiting approval by the U.S. Food and Drug Administration.

Thirty-one medicines to treat HIV/AIDS have been approved since scientists first identified the virus that causes AIDS more than 20 years ago. The first HIV/AIDS medicine was approved in 1987, just four years after the virus was identified.

Although the U.S. Centers for Disease Control and Prevention (CDC) estimate that more than 1 million Americans were living with HIV infection at the end of 2006, the increased availability and utilization of newer prescription medicines has helped to reduce the U.S. death rate from AIDS substantially in recent years, according to government statistics. In fact, the CDC estimates that since the introduction of highly active anti-retroviral therapy in 1995, the annual number of deaths in the U.S. due to AIDS has dropped by more than 70 percent.

Despite this progress, AIDS remains a devastating and growing health problem in developing countries, particularly in sub-Saharan Africa, China, India and the Russian Federation. According to the Joint United Nations Programme on HIV/AIDS, in 2007 an estimated 33 million people were living with HIV, 2.7 million were newly infected with HIV, and 2 million people died from the disease.

From 2000 to 2007, America's pharmaceutical research and biotechnology companies contributed more than $9.2 billion to improve health care in the developing world, according to the International Federation of Pharmaceutical Manufacturers & Associations.

The projects they supported included clinics to treat patients with HIV/AIDS, education and prevention programs, initiatives to prevent mother-to-child transmission of HIV, and donations of medicines for AIDS and related diseases. A number of companies also provide AIDS drugs at reduced prices in many countries.

"As a result of HIV/AIDS medicines, a disease that was once a virtual death sentence can now be controlled and treated as if it were a chronic disease," states Tauzin. "And the new medicines our scientists are working on right now bring hope for even more promising results in the future."

"While researchers are making exciting progress in the search for new treatments for HIV/AIDS, these efforts are wasted if the medicines that are developed don't get to the patients who need them," says PhRMA Senior Vice President Ken Johnson.

Help is available to patients in need through the Partnership for Prescription Assistance (PPA), a program sponsored by America's pharmaceutical research companies. To date, the PPA has helped more than 6 million patients nationwide. Since its launch in April 2005, the PPA bus tour has visited all 50 states and more than 3,000 cities.

To read the report Medicines in Development for HIV/AIDS 2009 on the PhRMA Web site, go to:

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit

For information on the danger of imported drugs, visit:

SOURCE Pharmaceutical Research and Manufacturers of America

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase
2. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
3. Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015
4. Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015
5. Reportlinker Adds U.S. Market for PACS and EMR
6. Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective
7. Reportlinker Adds Holter Monitoring Systems - A Global Market Review
8. Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review
9. Reportlinker Adds Anesthesia Disposables - A World Market Review
10. Reported Use of AMAGs Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are On the Verge of Use
11. Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
Breaking Medicine Technology:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):